Podcast Episode · Lung Cancer Considered · 01/06/2026 · 31m

In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss daily highlights from the conference. Dr. Tin ...

In this episode of Lung Cancer Considered, host Dr. Stephen Liu sits down with Dr. Arsela Prelaj to explore what happens when cutting-edge artificial intelligen ...

Stephen V Liu: Join Discussion on Treating Rare Lung Cancer Subtypes at WCLC25 / cancer, Georgetown Lombardi Comprehensive Cancer Center, Merel Hennink,

This livestream is an opportunity to connect face-to-face with others who care about lung cancer. Our guest experts will discuss developments coming out of this year’s World Conference on Lung […]

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of taletrectinib, a next-generation ROS1 kinase inhibitor, for ...

In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case with Dr. Chunxia Su and Dr. Collin Blakely. The case explor ...

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses EGFR exon 20 insertions and the recently approved targeted therapy for this subset of ...

This episode of Lung Cancer Considered reviews important lung cancer data presented at ASCO 2025. Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephe ...

IRF progression-free survival and overall survival were longer in the lurbinectedin plus atezolizumab group than the atezolizumab group for patients with ES-SCLC, albeit with a higher incidence of adv...

This episode of Lung Cancer Considered reviews important lung cancer data presented at ASCO 2025. Lung Cancer Considered hosts Dr. Narjust Florez and Dr. Stephe ...

In this episode of Lung Cancer Considered, host Dr. Stephen Liu moderates a Virtual Tumor Board case with Dr. Mara Antonoff, Dr. Shankar Siva, and Dr. David Car ...

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of telisotuzumab vedotin, an antibody-drug conjugate, for NSCL ...

In this episode of Lung Cancer Considered, host Dr. Stephen Liu speaks with Dr. Bryant Lin, Clinical Professor of Medicine at Stanford University and co-founder ...

This episode of Lung Cancer Considered takes an in-depth look at the microbiome-- what is it, and why is it important to lung cancer clinicians and researchers? ...

This IASLC Virtual Tumor Board episode focuses on a patient with stage III ALK-positive NSCLC. ALK fusions are present in about 5% of NSCLC and there are now si ...

Clinical trials to develop a lung cancer vaccine to treat or prevent the most deadly form of cancer in the U.S. could be available in “the next few years.”

2025 Texas Lung Cancer Conference Agenda

Neuregulin 1 (NRG1) fusions are recurrent oncogenic drivers found in multiple solid tumors. NRG1 binds to human epidermal growth factor receptor 3 (HER3), leading to heterodimerization with HER2 an...

Median overall survival improvement expected to exceed one year First and only regimen with a survival benefit over current standard of care in first-line treatment of EGFR-mutated lung cancer

In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of perioperative nivolumab based on the Phase III CheckMa ...

This multicenter cohort study develops and assesses the validity of a deep learning model for predicting immune checkpoint inhibitor response in patients with advanced non−small cell lung cancer.

Treatment with adjuvant osimertinib for three years is the standard-of-care for resected stage IB-IIIA non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR)-mutations. The role of neoadjuvant osimertinib in the perioperative setting is yet to be elucidated in the NeoADAURA study (NCT04351555).

PURPOSEThe concept of time toxicity of cancer treatment, defined as proportion of days from physical contact with the health care system, has been suggested as simple, patient-centered measure useful ...